Administration secures 10 million courses of Pfizer COVID-19 oral antiviral
The federal government will purchase 10 million treatment courses of the COVID-19 oral antiviral Paxlovid from Pfizer if the Food and Drug Administration approves or authorizes the drug for emergency use, the administration announced today. Pfizer has requested an emergency use authorization for the drug, which it says reduced the risk of COVID-19-related hospitalization or death by 89% in a phase 2/3 clinical trial. AHA will provide additional information regarding the drug’s distribution and uses once FDA approval is attained and the Administration shares its plans for allocating the available courses of medication.
Related News Articles
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…